updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
Published 2 years ago • 206 plays • Length 8:45Download video MP4
Download video MP3
Similar videos
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
7:23
cartitude-2: efficacy and safety of ciltacabtagene autoleucel in patients with progressive mm
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
2:01
an update on cohort c from the cartitude-2 trial
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
3:07
cilta-cel in lenalidomide-refractory mm patients: updates from cohort a of the cartitude-2 trial
-
5:34
latest results from the cartitude-2 study testing cilta-cel in multiple myeloma patients
-
7:25
cilta-cel continues to show promise as a treatment for progressive multiple myeloma
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
7:41
cartitude-2: ciltacabtagene autoleucel in patients with progressive multiple myeloma
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm
-
6:54
ash23: cartitude-2 trial on ciltacabtagene autoleucel in multiple myeloma | jens hillengass, md, phd
-
1:17
efficacy & safety of standard of care cilta-cel in r/r multiple myeloma
-
59:53
clinical trials in multiple myeloma
-
2:05
meta-analysis of cilta-cel in patients with r/r multiple myeloma
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma